Latest news with #GENCURIX
Yahoo
19-06-2025
- Business
- Yahoo
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics company is the first development partner under QIAGEN's QIAcuityDx Partnering Program, designed to enable the generation of a broad menu of in-vitro diagnostics (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics. The latest development is expected to significantly boost the company's Precision Diagnostics business under the Diagnostic Solutions product group. Shares of QIAGEN stayed flat in the aftermarket following the announcement of the news yesterday. The collaboration with GENCURIX represents the first step in building a robust and innovative assay ecosystem for the QIAcuityDx platform, backed by QIAGEN's distribution capabilities and technical support. Accordingly, market sentiment surrounding QGEN stock should stay positive, driven by the news. QIAGEN has a market capitalization of $10.35 billion. The company has an earnings yield of 5%, well above the industry's -29.3% yield. In the trailing four quarters, it delivered an average earnings surprise of 4.9%. The QIAcuityDx Partnering Program aims to support third-party assay development on QIAcuityDx. A member of the QIAcuity family of dPCR systems, the platform had more than 2,700 cumulative placements since its launch by the end of 2024. These menu initiatives for clinical applications will leverage this installed base and build on the 2024 milestone of launching more than 130 new assays for QIAcuity for research applications, complemented by the extensive menu of custom assays available on QIAGEN's GeneGlobe platform. Image Source: Zacks Investment Research Under this first partnership, GENCURIX will apply its proven expertise in complex, multiplex IVD assay development to create oncology tests. GENCURIX will begin developing multiple oncology assays and pursue IVD regulatory approvals. As the legal manufacturer of the assays, GENCURIX will be fully responsible for obtaining and maintaining all necessary regulatory approvals and certifications. Upon approval, the assays will be marketed through QIAGEN's global commercial infrastructure as part of the QIAcuityDx Partnering Program, ensuring streamlined access for laboratories worldwide. Per a research report, the global IVD market was valued at $108.30 billion in 2024 and is expected to grow at a compound annual rate of 5.6% through 2030. The growing demand for accurate, rapid and personalized diagnostic solutions globally is fueling the market's growth. The expansion is also supported by the integration of digital health, AI and data analytics into diagnostic platforms, helping enhance test accuracy and clinical decision-making. Last week, the company announced a new global collaboration with Incyte to develop a novel diagnostic panel to support the latter's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Under the agreement terms, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. Over the past year, QGEN shares have risen 8.1% against the industry's 16.1% decline. QIAGEN currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 35.1% in the past year compared with the industry's 7.7% growth. Its earnings yield of 8.5% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.8% in the past year. Estimates for the company's 2025 earnings per share have jumped 2.8% to 73 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Cencora's fiscal 2025 earnings per share have increased 0.4% to $15.75 in the past 30 days. Shares of the company have jumped 25.9% in the past year against the industry's 16.2% fall. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
18-06-2025
- Business
- Business Wire
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. GENCURIX is the first development partner under QIAGEN's QIAcuityDx Partnering Program. This important advancement marks a significant step towards establishing a broad menu of in vitro diagnostic (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics. The new partnership combines QIAGEN's QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX's expertise in multiplex assay development. The aim is to enable the creation of oncology IVD assays for both tissue and liquid biopsy applications, with flexible commercialization options and global reach through QIAGEN's Partnering Program. 'The QIAcuityDx Partnering Program is designed to enable the generation of a broad menu of IVD assays on the platform,' said Jonathan Arnold, Vice President and Head, Partnering for Precision Diagnostics at QIAGEN. 'The first partnership in this program with GENCURIX is an exciting moment, giving our oncology testing customers access to high-quality IVD assays that complement other established methods such as qPCR and NGS. We look forward to working with GENCURIX within this promising partner program.' 'This strategic partnership with QIAGEN represents a major inflection point for expanding our oncology molecular diagnostic technologies into the global market,' said Sang Rae Cho, CEO at GENCURIX. 'We are confident that the synergy between our diagnostic content and QIAGEN's platform will lead to global-standard precision cancer diagnostic solutions.' The QIAcuityDx Partnering Program aims to support third-party assay development on QIAcuityDx, which is a member of the QIAcuity family of digital PCR systems that reached at the end of 2024 more than 2,700 cumulative placements since launch. These menu initiatives for clinical applications will leverage this installed base as well as build on the 2024 milestone of launching more than 130 new assays for QIAcuity for research applications, and complemented by the extensive menu of custom assays available on QIAGEN's GeneGlobe platform at GENCURIX will apply its proven expertise in complex, multiplex IVD assay development to create oncology tests The QIAcuityDx Four platform delivers a scalable and high-performance digital PCR solution for clinical laboratories. As global adoption of digital PCR grows, it is increasingly recognized as a complementary method to qPCR and NGS—particularly in oncology, infectious diseases, and rare genetic disorders. Through the QIAcuityDx Partnering Program, QIAGEN is opening its platform to third-party developers, encouraging innovation in order to offer laboratories a continuously expanding range of validated diagnostic tests. GENCURIX will begin developing multiple oncology assays and pursue IVD regulatory approvals. GENCURIX, as the legal manufacturer of the assays, will be fully responsible for obtaining and maintaining all necessary regulatory approvals and certifications. Upon approval, the assays will be marketed through QIAGEN's global commercial infrastructure as part of the QIAcuityDx Partnering Program, ensuring streamlined access for laboratories worldwide. By enabling third-party development, QIAGEN is addressing the growing demand for broader access to high-precision and cost-efficient diagnostic assays. The collaboration with GENCURIX represents the first step in building a robust and innovative assay ecosystem for the QIAcuityDx platform, backed by QIAGEN's distribution capabilities and technical support. For more information about the QIAcuityDx Partnering Program please visit: About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit About GENCURIX GENCURIX Inc. is a molecular diagnostics company based in Seoul, South Korea, focused on developing dPCR-based diagnostics and liquid biopsy platforms. Its products include GenesWell™ BCT, a breast cancer prognostic test, and Droplex™, a diagnostic assay series for companion and stratification testing in multiple cancer types. For more information, visit Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
